Werbung
Werbung

PHAT

PHAT logo

Phathom Pharmaceuticals, Inc. Common Stock

15.02
USD
Gesponsert
-0.58
-3.74%
09. Jan., 15:59 UTC -5
Geschlossen
exchange

Nach-Markt

15.49

+0.48
+3.19%

PHAT Ergebnisberichte

Positives Überraschungsverhältnis

PHAT übertreffen die 14 der letzten 25Schätzungen.

56%

Nächster Bericht

Datum des nächsten Berichts
04. März 2026
Estimate for Q4 25 (Revenue/ EPS)
$57.08M
/
-$0.39
Implizierte Änderung von Q3 25 (Revenue/ EPS)
+15.31%
/
-4.88%
Implizierte Änderung von Q4 24 (Revenue/ EPS)
+92.43%
/
-62.86%

Phathom Pharmaceuticals, Inc. Common Stock earnings per share and revenue

On 30. Okt. 2025, PHAT reported earnings of -0.41 USD per share (EPS) for Q3 25, beating the estimate of -0.55 USD, resulting in a 26.25% surprise. Revenue reached 49.50 million, compared to an expected 47.93 million, with a 3.28% difference. The market reacted with a -1.63% price change (close before vs. close after earnings).
Looking ahead to Q4 25, 11 analysts forecast an EPS of -0.39 USD, with revenue projected to reach 57.08 million USD, implying an decrease of -4.88% EPS, and increase of 15.31% in Revenue from the last quarter.
FAQ
For Q3 2025, Phathom Pharmaceuticals, Inc. Common Stock reported EPS of -$0.41, beating estimates by 26.25%, and revenue of $49.50M, 3.28% above expectations.
The stock price moved down -1.63%, changed from $13.53 before the earnings release to $13.31 the day after.
The next earning report is scheduled for 04. März 2026.
Based on 11 analysts, Phathom Pharmaceuticals, Inc. Common Stock is expected to report EPS of -$0.39 and revenue of $57.08M for Q4 2025.
Scheck FXEmpire's Earnings Calendar for today's list of reporting companies.
Werbung